期刊文献+

Learning from berberine: Treating chronic diseases through multiple targets 被引量:32

Learning from berberine: Treating chronic diseases through multiple targets
原文传递
导出
摘要 Although advances have been made, chemotherapy for chronic, multifactorial diseases such as cancers, Alzheimer's disease, cardiovascular diseases and diabetes is far from satisfactory. Agents with different mechanisms of action are required. The botanic compound berberine(BBR) has been used as an over-the-counter antibacterial for diarrhea in China for many decades. Recent clinical studies have shown that BBR may be therapeutic in various types of chronic diseases. This review addresses BBR's molecular mechanisms of action and clinical efficacy and safety in patients with type 2 diabetes, hyperlipidemia, heart diseases, cancers and inflammation. One of the advantages of BBR is its multiple-target effects in each of these diseases. The therapeutic efficacy of BBR may reflect a synergistic regulation of these targets, resulting in a comprehensive effect against these various chronic disorders. The safety of BBR may be due to its harmonious distribution into those targets. Although the single-target concept is still the principle for drug discovery and research, this review emphasizes the concept of a multiple target strategy, which may be an important approach toward the successful treatment of multifactorial chronic diseases. Although advances have been made, chemotherapy for chronic, multifactorial diseases such as cancers, Alzheimer's disease, cardiovascular diseases and diabetes is far from satisfactory. Agents with different mechanisms of action are required. The bo- tanic compound berberine (BBR) has been used as an over-the-counter antibacterial for diarrhea in China for many decades. Recent clinical studies have shown that BBR may be therapeutic in various types of chronic diseases. This review addresses BBR's molecular mechanisms of action and clinical efficacy and safety in patients with type 2 diabetes, hyperlipidemia, heart diseases, cancers and inflammation. One of the advantages of BBR is its multiple-target effects in each of these diseases. The therapeutic efficacy of BBR may reflect a synergistic regulation of these targets, resulting in a comprehensive effect against these various chronic disorders. The safety of BBR may be due to its harmonious distribution into those targets. Although the single-target concept is still the principle for drug discovery and research, this review emphasizes the concept of a multiple target strategy, which may be an important approach toward the successful treatment of multifactorial chronic diseases.
出处 《Science China(Life Sciences)》 SCIE CAS CSCD 2015年第9期854-859,共6页 中国科学(生命科学英文版)
基金 supported by the National Mega-Project for Drug Research&Development,China(to Jiang Jian Dong)
关键词 慢性疾病 治疗 靶点 阿尔茨海默氏病 2型糖尿病 临床疗效 BBR 心血管疾病 chronic multifactorial diseases,drug treatment,berberine,multiple-target
  • 相关文献

参考文献57

  • 1Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang J D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 2004, 10:1344-1351.
  • 2Huang Z J, Zeng Y, Lan P, Sun P H, Chen W M. Advances in struc- tural modifications and biological activities of berberine: An active compound in traditional Chinese medicine. Mini Rev Med Chem, 2011, 11:1122-1129.
  • 3Xie Q, Johnson B R, Wenckus C S, Fayad M I, Wu C D. Efficacy of berberine, an antimicrobial plant alkaloid, as an endodontic irrigant against a mixed-culture biofilm in an in vitro tooth model. J Endod, 2012, 38:1114-1117.
  • 4Chen Q M, Xie M Z. Studies on the hypoglycemic effect of Coptis chinensis and berberine (in Chinese). Yao Xue Xue Bao, 1986, 21: 401406.
  • 5Lee Y S, Kim W S, Kim K H, Yoon M J, Cho H J, Shen Y, Ye J M, Lee C H, Oh W K, Kim C T, Hohnen-Behrens C, Gosby A, Kraegen E W, James D E, Kim J B. Berberine, a natural plant product, acti- vates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 2006, 55: 2256- 2264.
  • 6Zhang H, Kong W J, Shan Y Q, Song D Q, Li Y, Wang Y M, You X F, Jiang J D. Protein kinase D activation stimulates the transcription of the insulin receptor gene. Mol Cell Endocrinol, 2010, 330:25-32.
  • 7Chert C, Zhang Y, Huang C. Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun, 2010, 397: 543-547.
  • 8Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, Yang D, Liang H, Ye J, Weng J. Berberine impro,Jes glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS ONE, 2011, 6: e 16556.
  • 9Han J, Lin H, Huang W. Modulating gut microbiota as an anti- diabetic mechanism of berberine. Med Sci Monit, 2011, 17: RA164-167.
  • 10Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, Li X, Ning G, Zhao L. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insu- lin resistance in high-fat diet-fed rats. PLoS ONE, 2012, 7:e42529.

同被引文献279

引证文献32

二级引证文献234

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部